Shopping Cart
Remove All
Your shopping cart is currently empty
Depatuxizumab (Synonyms: ABT-806, ABT806)
Catalog No. T78326 Copy Product Info
🥰Excellent
Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN).
Depatuxizumab
Copy Product Info🥰Excellent
Catalog No. T78326
Synonyms ABT-806, ABT806
Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN).
Depatuxizumab
Cas No. 1471999-69-5
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $415 | - | In Stock | |
| 5 mg | $1,230 | - | In Stock | |
| 10 mg | $1,990 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.0% (SDS-PAGE); 99.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN). |
| In vivo | Depatuxizumab (10, 40 mg/kg, intraperitoneal injection, 3 times a week for 2 weeks) can significantly inhibit tumor growth in the U87MGde2-7 glioblastoma multiforme (GBM) model and A431 squamous cell carcinoma model of Nu/Nu mice. Depatuxizumab (10, 40 mg/kg, intraperitoneal injection, 3 times a week for 2 weeks) can inhibit tumor growth and pEGFR levels in the EGFRvIII-positive GBM-SN0199-PDX model of NSG mice. [1] |
| Synonyms | ABT-806, ABT806 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | ERBB1/EGFR/HER1 |
| Molecular Weight | 144.53 kDa |
| Cas No. | 1471999-69-5 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Depatuxizumab | purchase Depatuxizumab | Depatuxizumab cost | order Depatuxizumab | Depatuxizumab in vivo | Depatuxizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.